The pyomyositis market is poised to reach a value pool of USD 25 billion by 2023 and surge ahead with a CAGR of 4.8% to reach USD 40 billion in 2033, according to Future Market Insights.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value in 2023 | USD 25 billion |
| Projected Market Value in 2033 | USD 40 billion |
| Growth Rate (2023 to 2033) | 4.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
Recent Developments in the Pyomyositis Market
Pyomyositis indicates swelling in body tissue which leads to the accumulation of pus caused by bacterial infection of skeletal muscles. Patients of all age group can be diagnosed with pyomyositis, majority of which includes children aged 2 to 5 years and patients with immunodeficiency disorders.
Pyomyositis can be treated by administration of antibiotics and surgical drainage in case of severe infection. According to study conducted in Uganda on pyomyositis, it is more prevalent in tropical regions and accounts for 1-4% hospitalization.
Pyomyositis market is expected to observe downfall amid Covid-19 due to the decline in hospitalization and surgical procedures across the globe. There has been a disruption in the supply and demand of pyomyositis treatment drugs due to shift in healthcare priorities and fear of infections in the healthcare facilities.
Ongoing clinical trials are expected to delay and short-term, negatively impacting the market. However, the shift will become normal in coming 1-2 years and expected to rise diagnosis and treatment rates of pyomyositis market.
Global pyomyositis market is anticipated to grow owing to increasing prevalence of the musculoskeletal surgical conditions in the future. Development of advanced surgical technologies are expected to accelerate the growth of the pyomyositis market in the future.
In addition, rising healthcare expenditure and early diagnosis is expected to boost global pyomyositis market. The rise in investments for research and development activities propelling the pyomyositis market growth.
Unavailability of effective treatment can hinder pyomyositis market growth. Generic drugs and biosimilar may hamper the growth of global pyomyositis market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Pyomyositis treatment usually involves a combination of drugs, by drug class, antibiotics segment is expected to hold the largest share of revenue in the pyomyositis market. Oral route of administration is more prominent in the treatment of pyomyositis as compared to the parenteral route of administration.
Among distribution channels, the hospital pharmacies segment is projected to contribute the highest revenue in the pyomyositis market during the forecast period. Online pharmacies segment is estimated to observe fasted growing in the pyomyositis market due to increased penetration of e-commerce.
North America is expected to continue dominating the pyomyositis market owing to the high rate of prevalence in the region during the forecast period. Europe is the second lucrative region in pyomyositis market owing to early diagnosis and technological advancements.
Asia-Pacific pyomyositis market is estimated to have the highest growth owing to high patient pool and rise in medical tourism in the region. The Middle East and Africa pyomyositis market are still an untapped market with poor healthcare infrastructure and poor access to treatment.
Some of the key participants in the pyomyositis market identified are
The research report on Pyomyositis market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report on Pyomyositis market provides analysis and information according to market segments such as drug class, route of administration, application, and region.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Drug Class 6.2. Route Of Administration 6.3. Distribution Channels 7. Global Market Analysis and Forecast, By Drug Class 7.1. Corticosteroids 7.2. Immunosuppressants 7.3. Anti-Rheumatic Drugs 7.4. Antibiotics 8. Global Market Analysis and Forecast, By Route Of Administration 8.1. Oral 8.2. Parenteral 9. Global Market Analysis and Forecast, By Distribution Channels 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Online Pharmacies 9.4. Drug Stores 10. Global Market Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. South Asia 10.5. East Asia 10.6. Oceania 10.7. Middle East and Africa 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Europe Sales Analysis and Forecast, by Key Segments and Countries 14. South Asia Sales Analysis and Forecast, by Key Segments and Countries 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries 16. Oceania Sales Analysis and Forecast, by Key Segments and Countries 17. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries 18. Sales Forecast by Drug Class, Route Of Administration, and Distribution Channels for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Novartis AG 20.2. Merck & Co. 20.3. Mallinckrodt 20.4. Akorn 20.5. Amgen Inc 20.6. Bausch Health 20.7. Pfizer Inc. 20.8. Corbus Pharmaceuticals Holdings Inc. 20.9. IDERA 20.10. Mallinckrodt 20.11. Genentech 20.12. AbbVie Inc. 20.13. GlaxoSmithKline plc. 20.14. Milo Biotechnology 20.15. CytRx Corporation 20.16. Sanofi Promega 20.17. AstraZeneca
Explore Healthcare Insights
View Reports
Pyomyositis Market
